SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX

SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 438.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,202 shares of the biopharmaceutical company’s stock after purchasing an additional 234,629 shares during the period. SG Americas Securities LLC’s holdings in Royalty Pharma were worth $11,136,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. CWM LLC raised its stake in Royalty Pharma by 1.5% in the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 281 shares in the last quarter. GAMMA Investing LLC boosted its position in Royalty Pharma by 9.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 289 shares in the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of Royalty Pharma by 1.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock worth $1,037,000 after acquiring an additional 289 shares during the period. Merit Financial Group LLC grew its holdings in shares of Royalty Pharma by 3.5% during the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock worth $323,000 after acquiring an additional 306 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

RPRX has been the topic of several research reports. Weiss Ratings upgraded Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, February 12th. Leerink Partners set a $45.00 price objective on Royalty Pharma in a report on Thursday, December 11th. Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Citigroup boosted their target price on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Finally, UBS Group raised shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Friday, January 30th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and a consensus target price of $48.67.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $45.53, for a total transaction of $1,584,034.23. Following the completion of the transaction, the chief financial officer directly owned 43,886 shares of the company’s stock, valued at $1,998,129.58. This trade represents a 44.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 532,287 shares of company stock valued at $22,215,917. 18.90% of the stock is owned by company insiders.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $46.35 on Monday. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The stock has a fifty day simple moving average of $44.42 and a two-hundred day simple moving average of $40.28. Royalty Pharma PLC has a 12-month low of $29.66 and a 12-month high of $47.86. The stock has a market capitalization of $26.74 billion, a price-to-earnings ratio of 34.33 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million for the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. On average, research analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were given a dividend of $0.235 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend was Friday, February 20th. This represents a $0.94 annualized dividend and a yield of 2.0%. Royalty Pharma’s payout ratio is currently 69.63%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.